RGNX
Price
$6.76
Change
-$0.39 (-5.45%)
Updated
Apr 1 closing price
Capitalization
358.37M
28 days until earnings call
VYGR
Price
$3.37
Change
-$0.01 (-0.30%)
Updated
Apr 1 closing price
Capitalization
186.05M
41 days until earnings call
Ad is loading...

RGNX vs VYGR

Header iconRGNX vs VYGR Comparison
Open Charts RGNX vs VYGRBanner chart's image
REGENXBIO
Price$6.76
Change-$0.39 (-5.45%)
Volume$1.03M
Capitalization358.37M
Voyager Therapeutics
Price$3.37
Change-$0.01 (-0.30%)
Volume$618.77K
Capitalization186.05M
RGNX vs VYGR Comparison Chart
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. VYGR commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a StrongBuy and VYGR is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (RGNX: $7.15 vs. VYGR: $3.38)
Brand notoriety: RGNX and VYGR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 119% vs. VYGR: 135%
Market capitalization -- RGNX: $358.37M vs. VYGR: $186.05M
RGNX [@Biotechnology] is valued at $358.37M. VYGR’s [@Biotechnology] market capitalization is $186.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileVYGR’s FA Score has 1 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • VYGR’s FA Score: 1 green, 4 red.
According to our system of comparison, VYGR is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 4 TA indicator(s) are bullish while VYGR’s TA Score has 4 bullish TA indicator(s).

  • RGNX’s TA Score: 4 bullish, 6 bearish.
  • VYGR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VYGR is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -17.82% price change this week, while VYGR (@Biotechnology) price change was -13.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

RGNX is expected to report earnings on Apr 30, 2025.

VYGR is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($358M) has a higher market cap than VYGR($186M). RGNX YTD gains are higher at: -7.503 vs. VYGR (-40.388). VYGR has higher annual earnings (EBITDA): -78.56M vs. RGNX (-198.23M). VYGR has more cash in the bank: 267M vs. RGNX (235M). VYGR has less debt than RGNX: VYGR (43.7M) vs RGNX (82M). RGNX (83.3M) and VYGR (80M) have equivalent revenues.
RGNXVYGRRGNX / VYGR
Capitalization358M186M192%
EBITDA-198.23M-78.56M252%
Gain YTD-7.503-40.38819%
P/E RatioN/A6.00-
Revenue83.3M80M104%
Total Cash235M267M88%
Total Debt82M43.7M188%
FUNDAMENTALS RATINGS
RGNX vs VYGR: Fundamental Ratings
RGNX
VYGR
OUTLOOK RATING
1..100
6974
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
5890
P/E GROWTH RATING
1..100
197
SEASONALITY SCORE
1..100
n/a43

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYGR's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for RGNX (76). This means that VYGR’s stock grew somewhat faster than RGNX’s over the last 12 months.

VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that VYGR’s stock grew similarly to RGNX’s over the last 12 months.

VYGR's SMR Rating (95) in the Biotechnology industry is in the same range as RGNX (98). This means that VYGR’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (58) in the Biotechnology industry is in the same range as VYGR (90). This means that RGNX’s stock grew similarly to VYGR’s over the last 12 months.

VYGR's P/E Growth Rating (7) in the Biotechnology industry is in the same range as RGNX (19). This means that VYGR’s stock grew similarly to RGNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXVYGR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 14 days ago
75%
Bullish Trend 20 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NOINX15.08N/A
N/A
Northern International Equity Index
NMIMX25.94N/A
N/A
Columbia Large Cap Enhanced Core Inst
MSTGX9.65N/A
N/A
Morningstar Global Income
ELMFX16.24N/A
N/A
Lord Abbett Emerging Markets Equity F
OAZEX19.25-0.40
-2.04%
Oakmark International Small Cap R6